Tyra Bioscience (TYRA) Price & Analysis

Compare

91 Followers

TYRA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.42 - $29.60

Previous CloseN/A

Volume80.11K

Average Volume (3M)210.62K

Market Cap

$673.68M

Enterprise Value$279.65M

Total Cash (Recent Filing)$296.27M

Total Debt (Recent Filing)$6.02M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Oct 30, 2025

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding53,297,140

10 Day Avg. Volume227,792

30 Day Avg. Volume210,617

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.42

Enterprise Value/Revenue563.82

Enterprise Value/Gross Profit-14.72K

Enterprise Value/Ebitda-2.31

Forecast

1Y Price Target

$30.25

Price Target Upside139.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe first patient has been dosed in the Phase 2 trial of TYRA-300, a selective FGFR3 inhibitor, in low-grade, intermediate risk non-muscle invasive bladder cancer.

Economic IncentiveThere may be an important economic incentive for community urologists to prescribe TYRA-300, as it may be prescribed through a popular group purchasing organization, UroGPO.

Market AdvantageTYRA-300 could be favored over alternative options in NMIBC due to its oral route of administration, offering greater convenience and quality of life.

Bears Say

Competitive LandscapeTYRA-300 is an FGFR3-selective inhibitor that was designed to have 20- to 70-fold higher selectivity for FGFR3 compared to existing pan-FGFR inhibitors.

Treatment LimitationsIf a patient does not experience a complete response on TYRA-300, they can ultimately undergo TURBT as a backup option.

Tyra Bioscience News

Tyra Biosciences says first child dosed in BEACH301 trial

Tyra Biosciences (TYRA) announced that the first child has been dosed in BEACH301, a Phase 2 clinical study...

8d ago

TYRA

Tyra Biosciences reports Q2 EPS (47c), consensus (51c)

As of June 30, Tyra had cash, cash equivalents, and marketable securities of $296.3M. Tyra’s current cash, cash...

14d ago

TYRA

Tyra Bioscience’s Promising Developments in NMIBC and Achondroplasia Drive Buy Rating

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Tyra Bioscience and keeping the price target...

7d ago

TYRA

Tyra Bioscience Begins Phase 2 Study for Achondroplasia

An announcement from Tyra Bioscience ( ($TYRA) ) is now available. On August 21, 2025, Tyra Biosciences announced...

7d ago

TYRA

Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating...

13d ago

TYRA

Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Tyra Bioscience and keeping the price target...

14d ago

TYRA

Tyra Biosciences Advances Clinical Programs with Strong Financial Backing

Tyra Bioscience, Inc ( ($TYRA) ) has released its Q2 earnings. Here is a breakdown of the information...

14d ago

TYRA

Tyra Biosciences announces presentation on TYRA-300 preclinical results at ENDO

Tyra Biosciences (TYRA) announced that a late-breaking abstract has been accepted for presentation at The Endocrine Society’s Annual...

2M ago

TYRA

Promising Outlook for Tyra Bioscience: Buy Rating Driven by TYRA-300’s Potential in NMIBC Treatment

Tyra Bioscience (TYRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

TYRA

Tyra Bioscience Launches Phase 2 Study for TYRA-300

Tyra Bioscience ( ($TYRA) ) has issued an announcement. On June 30, 2025, Tyra Biosciences announced the commencement...

2M ago

TYRA

Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300

Tyra Biosciences (TYRA) announced that the first patient has been dosed in the Phase 2 SURF302 clinical trial...

2M ago

TYRA

Tyra Biosciences up 3% as RA Capital increases stake to 22.4%

In a regulatory 13D/A filing, RA Capital disclosed that it has increased its stake in Tyra Biosciences (TYRA)...

3M ago

TYRA

Tyra Bioscience Holds 2025 Annual Stockholders Meeting

Tyra Bioscience ( ($TYRA) ) just unveiled an update. On May 29, 2025, Tyra Biosciences held its 2025...

3M ago

TYRA

Tyra Biosciences management to meet with Oppenheimer

Meeting to be held on June 4 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

TYRA

TYRA FAQ

What was Tyra Bioscience’s price range in the past 12 months?

Tyra Bioscience lowest stock price was $6.42 and its highest was $29.60 in the past 12 months.

What is Tyra Bioscience’s market cap?

Tyra Bioscience’s market cap is $673.68M.

When is Tyra Bioscience’s upcoming earnings report date?

Tyra Bioscience’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.

How were Tyra Bioscience’s earnings last quarter?

Tyra Bioscience released its earnings results on Aug 14, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.529 by $0.059.

Is Tyra Bioscience overvalued?

According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tyra Bioscience pay dividends?

Tyra Bioscience does not currently pay dividends.

What is Tyra Bioscience’s EPS estimate?

Tyra Bioscience’s EPS estimate is -0.5.

How many shares outstanding does Tyra Bioscience have?

Tyra Bioscience has 53,297,140 shares outstanding.

What happened to Tyra Bioscience’s price movement after its last earnings report?

Tyra Bioscience reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.529. Following the earnings report the stock price went up 0.28%.

Which hedge fund is a major shareholder of Tyra Bioscience?

Currently, no hedge funds are holding shares in TYRA

Tyra Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

-31.21%

Trailing 12-Months

Asset Growth

-18.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tyra Bioscience

Tyra Bioscience (TYRA) is a biotechnology company focused on developing targeted therapies for cancer treatment. The company operates within the life sciences sector, specializing in precision medicine aimed at addressing oncogenic mutations. Tyra Bioscience's core product pipeline includes small molecule inhibitors designed to target specific genetic alterations in cancer cells, enhancing treatment efficacy and reducing side effects.

Tyra Bioscience (TYRA) Earnings & Revenues

Historic Earnings Reports

TYRA Stock 12 Month Forecast

Average Price Target

$30.25

▲(139.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","34":"$34","13.75":"$13.75","20.5":"$20.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.75,20.5,27.25,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,12.11076923076923,13.85153846153846,15.592307692307692,17.333076923076923,19.073846153846155,20.814615384615387,22.555384615384618,24.29615384615385,26.03692307692308,27.777692307692313,29.518461538461544,31.25923076923077,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,11.899230769230769,13.428461538461537,14.957692307692307,16.486923076923077,18.01615384615385,19.545384615384613,21.074615384615385,22.603846153846156,24.133076923076924,25.662307692307692,27.191538461538464,28.72076923076923,{"y":30.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,11.726153846153846,13.082307692307692,14.438461538461539,15.794615384615383,17.15076923076923,18.506923076923076,19.863076923076925,21.21923076923077,22.575384615384614,23.931538461538462,25.28769230769231,26.643846153846155,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.84,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >